A Phase 1 Double Blind Randomized Placebo Controlled Study To Destination was a phase 3, multicentre, randomised, double blind, placebo controlled, parallel group long term extension study to evaluate the safety and efficacy of subcutaneous. This article describes the design and objectives of the phase 3 des tination study in adults and adolescents with severe, uncontrolled asthma.
Summary Conclusions In This Phase 3 Randomized Double Blind A multicentre, double blind, randomized, placebo controlled, parallel group, phase 3, safety extension study to evaluate the safety and tolerability of tezepelumab in adults and adolescents with severe uncontrolled asthma (destination). The efficacy, safety and oral corticosteroid sparing potential of tezepelumab are being investigated in two ongoing, phase 3, randomized, double blind, placebo controlled studies (navigator [nct03347279] and source [nct03406078]). The efcacy, safety and oral corticosteroid sparing potential of tezepelumab are being investigated in two ongoing, phase 3, randomized, double blind, placebo controlled studies (navigator [nct03347279] and source [nct03406078]). A multicenter, randomized, double blind, placebo controlled, parallel group, phase 3 study to evaluate the efficacy and safety of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (copd).
Subject Disposition Pooled Randomized Double Blind Download The efcacy, safety and oral corticosteroid sparing potential of tezepelumab are being investigated in two ongoing, phase 3, randomized, double blind, placebo controlled studies (navigator [nct03347279] and source [nct03406078]). A multicenter, randomized, double blind, placebo controlled, parallel group, phase 3 study to evaluate the efficacy and safety of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (copd).
Comments are closed.